194 related articles for article (PubMed ID: 22217951)
21. Stimulant dosing in the community treatment of adult attention-deficit/hyperactivity disorder.
Olfson M; Marcus SC; Zhang HF; Wan GJ
J Clin Psychopharmacol; 2008 Apr; 28(2):255-7. PubMed ID: 18344749
[No Abstract] [Full Text] [Related]
22. Attention-deficit/hyperactivity disorder: the road traveled and the road ahead.
Jun A
Am J Health Syst Pharm; 2009 Nov; 66(22):2003. PubMed ID: 19890082
[No Abstract] [Full Text] [Related]
23. Lisdexamfetamine.
Blick SK; Keating GM
Paediatr Drugs; 2007; 9(2):129-35; discussion 136-8. PubMed ID: 17407369
[TBL] [Abstract][Full Text] [Related]
24. Lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder in adults.
Rostain AL
Curr Psychiatry Rep; 2009 Oct; 11(5):341-2. PubMed ID: 19785973
[No Abstract] [Full Text] [Related]
25. Molecule of the month: lisdexamfetamine mesilate.
Drug News Perspect; 2007 Mar; 20(2):138. PubMed ID: 17440637
[No Abstract] [Full Text] [Related]
26. Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.
Dew RE; Kollins SH
Expert Opin Pharmacother; 2010 Dec; 11(17):2907-13. PubMed ID: 20979573
[TBL] [Abstract][Full Text] [Related]
27. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
Wigal SB; Chae S; Patel A; Steinberg-Epstein R
Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
[TBL] [Abstract][Full Text] [Related]
28. Traumatic brain injury-related attention deficits: treatment outcomes with lisdexamfetamine dimesylate (Vyvanse).
Tramontana MG; Cowan RL; Zald D; Prokop JW; Guillamondegui O
Brain Inj; 2014; 28(11):1461-72. PubMed ID: 24988121
[TBL] [Abstract][Full Text] [Related]
29. Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder: An interrupted time-series analysis.
Bruno C; Zoega H; Gillies MB; Havard A; Coghill D; Pearson SA; Brett J
Aust N Z J Psychiatry; 2023 Jul; 57(7):1073-1076. PubMed ID: 37122132
[No Abstract] [Full Text] [Related]
30. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
Nikles CJ; Mitchell GK; Del Mar CB; Clavarino A; McNairn N
Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846
[TBL] [Abstract][Full Text] [Related]
31. Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults.
Faraone SV
J Atten Disord; 2012 Feb; 16(2):128-37. PubMed ID: 20837983
[TBL] [Abstract][Full Text] [Related]
32. Methylphenidate versus dextroamphetamine in ADHD.
Efron D
J Am Acad Child Adolesc Psychiatry; 1999 May; 38(5):500. PubMed ID: 10230180
[No Abstract] [Full Text] [Related]
33. Effect of lisdexamfetamine dimesylate on sleep in children with ADHD.
Giblin JM; Strobel AL
J Atten Disord; 2011 Aug; 15(6):491-8. PubMed ID: 20574056
[TBL] [Abstract][Full Text] [Related]
34. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
Ermer J; Homolka R; Martin P; Buckwalter M; Purkayastha J; Roesch B
J Clin Pharmacol; 2010 Sep; 50(9):1001-10. PubMed ID: 20173084
[TBL] [Abstract][Full Text] [Related]
35. Stimulant therapy in attention deficit/hyperactivity disorder.
Baldwin RL
J Ark Med Soc; 2003 Dec; 100(6):203-6. PubMed ID: 14661403
[TBL] [Abstract][Full Text] [Related]
36. [Basics of the drug therapy for attention deficit hyperactivity disorders in adolescents].
Airaksinen E; Airaksinen MM
Duodecim; 2003; 119(16):1553-62. PubMed ID: 14535028
[No Abstract] [Full Text] [Related]
37. What place for lisdexamfetamine in children and adolescents with ADHD?
Drug Ther Bull; 2013 Oct; 51(10):114-7. PubMed ID: 24113146
[TBL] [Abstract][Full Text] [Related]
38. [Stimulant therapy in children].
Steinhausen HC
Pharmacopsychiatria; 1982 Nov; 15(6):181-2. PubMed ID: 6130534
[No Abstract] [Full Text] [Related]
39. Clinical practice. Attention deficit-hyperactivity disorder.
Rappley MD
N Engl J Med; 2005 Jan; 352(2):165-73. PubMed ID: 15647579
[No Abstract] [Full Text] [Related]
40. New drugs: aliskiren hemifumarate, lisdexamfetamine dimesylate, and lapatinib.
Hussar DA
J Am Pharm Assoc (2003); 2007; 47(3):425-6, 428-30. PubMed ID: 17510042
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
